G arrison et al. 1 should be commended for launching a real-world comparison of high-dose (HD) versus standard-dose (SD) amoxicillin (80-90 vs 40-45 mg/kg/d, respectively) in 1999 when only laboratory data existed to support the use of HD amoxicillin. Despite the absence of clinical data, HD amoxicillin evolved into a first-choice antibiotic regimen for acute otitis media (AOM). Despite the originality of the study, many limitations make its conclusion regarding clinical efficacy suspect.
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Although the authors claim to be studying children at low risk for drug-resistant Streptococcus pneumoniae (DRSP), the entry criteria they permitted (eg, age >3 mo, day-care attendance, antibiotics in the previous month) conflict with more widely accepted definitions for patients at low risk for DRSP (eg, age >2 y, no day-care attendance, no antimicrobial exposure in preceding 3 mo). 2 In fact, 66% and 9% of the patients they studied were exposed to day care and received antibiotic therapy in the previous month, respectively. Despite including a majority of patients with at least one risk factor for DRSP, no clinical benefit was found in using HD amoxicillin. Why is this?
The financial limitation Garrison et al. describe, which permitted use of only clinical diagnosis and outcome as-sessment (pneumatic otoscopy and symptoms), is perhaps the biggest limitation of the study. Extremely large sample sizes (far greater than 151 total pts. included here) are required for antibiotic comparison trials in AOM when only clinical parameters are employed. Since 200-300 patients is the typical study limit that most funding agencies will sponsor, it is almost a guarantee that no difference will be found if only clinical parameters are utilized. In a recent presentation to the Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee, the sample sizes required for various designs of AOM studies were discussed. 3 According to the data presented, 542 total patients would be required to show that antibiotic A is superior to antibiotic B (assuming power 90%; clinical significance at p < 0.05; true clinical failure rates of 13% and 25%, respectively) when employing a study with only clinical diagnosis and outcomes assessment. 4 This represents an approximately 50% reduction in the clinical failure rate, similar to the assumption made by Garrison et al. in calculating their required sample size. However, Garrison et al. employed a less conservative power of 80% (acceptable to miss a true difference 20% of the time), not 90%. Despite 3 winter seasons of searching for patients, their study failed to meet the necessary samples size for their least-conservative estimate (ie, true failure rates for SD and HD amoxicillin of 20% and 10%, respectively).
Garrison et al. did post hoc power analyses for all situations where they found nonsignificant results (to gauge whether small sample size was the likely reason for the results). But in the manuscript we reviewed, the numerical results of these post hoc power analyses were not presented. Our own calculations, using their results, show that a sample size of approximately 14 000-18 000 patients (at a power of 0.80-0.90, respectively) would have been necessary to show a statistical difference in clinical efficacy between SD and HD amoxicillin, assuming it did exist. Inter-estingly, nearly 15 500 patients appear to be required to prove a true 2% difference in clinical efficacy for AOM between 2 antibiotics with 85% and 87% clinical efficacy, respectively. 4 Is the true difference in clinical efficacy between SD and HD amoxillin only about 2% in real-world practice settings (where bacterial and viral causes are never differentiated and spontaneous symptomatic resolution rates of 70-90% occur without antibiotics) 5 rather than the 5-10% difference assumed by Garrison et al. in their calculation of sample size? Nobody knows for sure, but the literature seems to suggest that many differences in clinical outcomes for otitis media are quite small. If the clinical efficacy difference truly is so small, which amoxicillin dose should be employed?
To our knowledge, only one other published randomized clinical trial has compared HD and SD amoxicillin, although not specifically in patients with only AOM. One study evaluated children with various respiratory tract illnesses (59% acute respiratory tract infection, 29% otitis media, 9% pneumonia, 3% sinusitis) to document any difference in the incidence of nasopharyngeal carriage with penicillin-nonsusceptible pneumococcus following treatment with HD versus SD amoxicillin. 6 Twenty-eight days after beginning either a short course of HD amoxicillin 90 mg/kg/d for 5 days (n = 398) or SD amoxicillin 40 mg/kg/d for 10 days (n = 397), the risk of resistant carriage was statistically less in the HD amoxicillin arm (24% vs 32%; RR 0.77). No difference was found in the frequency of adverse gastrointestinal effects between these dosage regimens (6% for HD vs 5% for SD). Garrison et al. also found the difference in frequency of reported adverse effects between HD and SD amoxicillin to not be significantly different (3% difference for both gastrointestinal distress and skin rash). The findings of these 2 studies 1,6 suggest that practitioners need not avoid HD amoxicillin because of fears of a greatly increased incidence of adverse effects compared with SD amoxicillin. Because of a lack of proven detriment from HD amoxicillin and potential benefit in reducing DRSP carriage, we feel that SD amoxicillin should be used only when the risk of DRSP appears extremely low.
The use of tympanocentesis, in addition to clinical parameters, dramatically lowers the necessary sample size in AOM studies. 3,4 Two hundred thirty-four total patients are necessary when bacteriologic diagnosis (ie, single initial tympanocentesis) combined with clinical outcomes is employed (assuming again 90% power and clinical failure rates for 2 antibiotics of 13% and 25%). The most manageable sample size, 30 total patients, occurs when both bacteriologic diagnosis and bacteriologic outcome (ie, initial combined with a repeat tympanocentesis during or soon after the completion of therapy, "double-tap") is added to clinical diagnosis/assessment.
In a 2002 meeting of the Anti-Infective Drugs Advisory Committee, the following question was posed to the voting membership: "Should the FDA require a study that incorporates tympanocentesis, not necessarily as the only evidence, but as one criterion for the approval of a drug that would be claimed to demonstrate efficacy in the treatment of acute otitis media?." 7 The vote (yes, 13; abstentions, 1) clearly reflected the added value that committee members saw in requiring manufacturers to determine the success or failure of their antibiotic on a bacteriologic rather than just a clinical basis. Despite the disadvantages of tympanocentesis (eg, pain, physician unfamiliarity, results not always correlated with clinical outcomes), it represents an additional tool that can bring greater objectivity into the determination of relative efficacy of antibiotic regimens for AOM. 7 Another element that would improve the design of randomized, double-blind comparisons of antibiotic regimens in AOM trials is the inclusion of a placebo arm, allowing a direct estimate of the treatment benefits of both standard and new antibiotic regimens. It provides a logical basis on which to plan upcoming active-controlled trials. Some pediatricians and investigative review boards may have clinical or legal concerns about using a placebo when the standard of care in the US historically has been to use an antibiotic.
The key to addressing these concerns is to exclude children at higher risk for poor outcomes if antibiotics are delayed (eg, initial temperature >37.5˚C, vomiting) 8 and to create a safety-net whereby antibiotics can be administered to children whose infections worsen or have slow resolution. Symptomatic relief with acetaminophen or ibuprofen can still be administered, and delayed prescriptions for antibiotics are given to caregivers of children in the placebo arm (caregivers have been adequately educated about the benefits and risks of immediate antibiotic therapy). Caregivers can, at their discretion, choose to fill the prescription at any time and treat children whose symptoms are slow to clear, persist, or worsen. In 2 recent trials of this type, only 24% (36/150) to 31% (55/175) of parents of children provided delayed antibiotic prescriptions actually filled their prescriptions, and 63-77% of parents were satisfied with this approach. 9, 10 We believe that future comparisons of antibiotic regimens for AOM should be randomized, double-blind, and include a placebo arm. At least one tympanocentesis should be done, along with clinical diagnosis and assessment, in an attempt to identify causative bacteria and their antibiotic sensitivities. A well-planned "double tap" study, combined with clinical diagnosis and outcomes assessment, requires the smallest sample size and represents the ideal design with the least amount of confounding factors, though it cannot and should not be employed in all study patients.
Initial and repeat tympanocentesis for trial patients must be used selectively according to perceived risks and benefits in each patient. We continue to support the initial use of HD amoxicillin (80-90 mg/kg/d) for AOM, as recommended by the Centers for Disease Control and Prevention's Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group 2 and other authors. 11 
